Trial Profile
Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin Lymphoma, Phase II
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Anaplastic large cell lymphoma; B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 13 Jan 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Results assessing extranodal Presentation in limited stage DLBCL as a prognostic marker in three sequential SWOG Trials S0014, S0313 and S1001 presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 29 Jan 2021 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.